Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies

Main Article Content

Jennifer Soung
Brett King
Christos Tziotzios
Lidia Rudnicka
Pascal Joly
Melinda Gooderham
Rodney Sinclair
Dalia Wajsbrot
Helen Tran
Robert Wolk


ritlecitinib, alopecia areata


1. Islam N, et al. Autoimmun Rev. 2015;14:81-89.

2. King B, et al. Lancet 2023;401:1518-1529.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>